相关实验视频
Updated: May 10, 2025

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
20.6K
儿童的血栓预防:在未知水域进行导航
1Department of Pediatric Hematology and Oncology, Erasmus University Medical Center Sophia Children's Hospital, Rotterdam, The Netherlands.
Hamostaseologie
|April 27, 2025
概括
儿科血栓瘤正在上升,需要在住院儿童中进行更好的预防. 目前的策略缺乏强有力的证据,需要对安全管理进行仔细的风险评估.
科学领域:
- 儿科血栓形成症 儿童血栓形成症
- 血管医学 血管医学
- 血液学 血液学 血液学
背景情况:
- 儿童血栓发生率每年增加近10%.
- 入院儿童特别容易受到静脉血栓栓塞 (VTE) 的影响.
- 现有的预防策略需要进一步基于证据的验证.
研究的目的:
- 审查目前关于儿童患者VTE预防的文献.
- 澄清特定儿科组的血栓预防策略.
- 确定儿科VTE预防的证据缺口.
主要方法:
- 现有文献的叙述性审查.
- 对儿科手术和医疗状况进行了集中分析.
- 探索血栓预防的指导方针.
主要成果:
- 对于儿科血栓预防中最佳实践的证据有限.
- 目前的策略是基于个别风险评估.
- 特定的患者群体 (例如,术后,白血病) 面临着独特的挑战.
结论:
- 儿童患者的有效VTE预防仍然是一个证据差距很大的领域.
- 由于没有明确的指导方针,临床医生必须平衡血栓和出血风险.
- 进一步的研究对于建立基于证据的儿童血栓预防方案至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
991
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
991
Disorders of Hemostasis
638
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
638
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Clot Retraction and Fibrinolysis
2.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.4K
Extrinsic and Intrinsic Pathways of Hemostasis
3.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
3.6K

